BIOCORP, announces the signature of an industrialization contract with Virbac, the 7th veterinary company worldwide.
BIOCORP, whose expertise and know-how are well-renowned, is thereby closing a deal in line with its strategy of creating new opportunities and manufacturing programs through specific developments implemented since 2015 (project-based services using BIOCORP’s expertise). Virbac Group, a company dedicated to animal health, employs over 4,800 people and has a global presence with subsidiaries in 31 countries, production centers in 11 countries and R&D centers on 5 continents.
The investment deal was closed after a 24-month collaboration between BIOCORP and Virbac for the development of a delivery device adapted to the needs of the veterinary laboratory. This device, an innovative administration and closure system for vials, is reusable and offers an optimal administration for products selected by Virbac.
The first deliveries are expected between the 1st and 2nd quarter of 2018. BIOCORP will then be responsible for the production of the industrialized product.
“We are thrilled to announce the signature of this industrialization contract with Virbac which successfully concludes the R&D program custom-developed by our teams. This collaboration with Virbac, an expert in animal health, highlights the width of our scope and the wide range of applications of our expertise,” commented Jacques Gardette and Eric Dessertenne, respectively founder and CEO, and Chief Operating Officer of BIOCORP.
